Annexin V-FITC / Propidium Iodide Flow Cytometric Quantification of Staurosporine-Induced Apoptosis in Jurkat T-Lymphocytes

Three independent biological replicates on separate days, each with technical duplicate tubes per condition. Dose-response: 0 (vehicle), 0.1, 0.5, 1.0, and 2.0 µM staurosporine at a single 6 h time point; plus a 1 µM time course (2, 6, 12, 24 h). A Z-VAD-FMK (50 µM, 1 h pre-treatment) co-condition tests caspase dependence. At least 10,000 single-cell events collected per tube within the gated population. Acquisition order randomized; voltages and compensation fixed within each experiment day.

BSL-2 for human Jurkat cells; biosafety cabinet for all open handling. Propidium iodide is a mutagen/DNA intercalator — wear gloves and collect PI-containing waste separately as hazardous. Staurosporine is a potent cytotoxic kinase inhibitor; handle as a hazardous drug with gloves and avoid aerosols. DMSO enhances skin penetration of co-dissolved compounds. The flow cytometer fluidics and sheath waste are biohazard — decontaminate with 10% bleach. Wear lab coat, nitrile gloves, eye protection; autoclave or bleach-treat biological waste.

Unstained cells (autofluorescence). Single-color controls: Annexin V-FITC-only and PI-only for compensation and quadrant placement. Vehicle control: DMSO-matched untreated cells defining the baseline viable (double-negative) gate. Positive apoptosis control: 1 µM staurosporine, 6 h. Necrosis control: cells heat-killed at 56 C for 10 min or treated with 0.1% saponin (AnnV-/PI+ or double-positive) to anchor the necrotic gate. Caspase-dependence control: Z-VAD-FMK to confirm the apoptotic signal is caspase-mediated.

Vehicle controls should show >=90% viable (double-negative). At 1 µM / 6 h, expect a clear rise in early-apoptotic AnnV+/PI- cells (~30-50%) with a smaller late-apoptotic fraction. By 24 h the population should shift toward AnnV+/PI+ (late apoptosis/secondary necrosis). Z-VAD-FMK should reduce the total AnnV+ fraction by >=50%. A clean experiment shows well-separated quadrants, low double-positive background in vehicle (<5%), and dose- and time-monotonic trends with tight duplicate agreement.

• Jurkat (clone E6-1) human T-lymphocyte cell line, mycoplasma-tested
• RPMI 1640, 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine
• Annexin V-FITC conjugate (per manufacturer titration, typically 5 µL/test)
• Propidium iodide (PI), 50 µg/mL stock, used at 1 µg/mL final
• 1x Annexin V binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
• Staurosporine, 1 mM stock in DMSO (working 0.1-2.0 µM)
• Z-VAD-FMK (pan-caspase inhibitor), 50 µM
• DMSO vehicle (matched <=0.1%)
• PBS (Ca2+/Mg2+-free) for washes
• 5 mL round-bottom flow tubes with 35 µm cell strainer caps
• Compensation beads (anti-mouse Ig kappa) for single-color controls

To establish a rigorously compensated, gated flow cytometry assay that distinguishes four cell states in suspension Jurkat cultures by combining phosphatidylserine externalization (Annexin V-FITC) with membrane integrity (PI exclusion). The assay generates quantitative percentages of viable (AnnV-/PI-), early-apoptotic (AnnV+/PI-), late-apoptotic (AnnV+/PI+), and necrotic (AnnV-/PI+) cells across a staurosporine dose-response.

1. Maintain Jurkat at 0.2-1.0 x 10^6 cells/mL; on assay day seed 0.5 x 10^6 cells/mL in fresh medium.
2. For caspase-inhibition arm, pre-treat with 50 µM Z-VAD-FMK for 1 h.
3. Add staurosporine (0.1-2.0 µM) or DMSO vehicle; incubate 37 C / 5% CO2 for the designated time.
4. Harvest 2-5 x 10^5 cells per tube; centrifuge 300 x g, 5 min, RT; do NOT discard supernatant cells (floaters are the dying fraction).
5. Wash once with cold PBS, then once with 1x Annexin binding buffer; resuspend in 100 µL binding buffer.
6. Add 5 µL Annexin V-FITC; incubate 15 min RT in the dark.
7. Add 400 µL binding buffer and 1 µg/mL PI immediately before acquisition (do not wash after PI).
8. Filter through a 35 µm strainer cap; keep on ice and acquire within 1 h.
9. On the cytometer, set FSC/SSC, gate single cells (FSC-H vs FSC-A), and collect >=10,000 gated events.
10. Apply compensation from single-color controls before quadrant gating.

Independent variables: staurosporine concentration (0-2.0 µM), exposure time (2-24 h), and Z-VAD-FMK presence. Dependent variables: percentage of cells in each quadrant (viable AnnV-/PI-, early AnnV+/PI-, late AnnV+/PI+, necrotic AnnV-/PI+). Controlled variables: cell density at treatment, passage number, Annexin V and PI concentrations, binding-buffer Ca2+ (essential for Annexin binding), time between PI addition and acquisition, cytometer voltages and compensation, and gating strategy.

We hypothesize that staurosporine induces apoptosis in a dose-dependent manner, with 1 µM for 4-6 h producing predominantly early-apoptotic (AnnV+/PI-) cells (~30-50%), progressing to late-apoptotic (AnnV+/PI+) populations by 12-24 h, and that the broad-caspase inhibitor Z-VAD-FMK (50 µM) significantly reduces the AnnV+ fraction, confirming caspase-dependent apoptosis.

FCS files are analyzed in FlowJo or FCS Express. Gating hierarchy: debris excluded on FSC/SSC -> singlets (FSC-H vs FSC-A) -> quadrant gate on Annexin V-FITC (FL1) vs PI (FL2/FL3) using single-color controls to set quadrants. Percentages per quadrant are exported per tube; total apoptosis is reported as (early + late) AnnV+ percentage. Background from vehicle is reported but not subtracted from raw percentages. Compensation matrices are computed from beads and applied uniformly. Gating templates are saved and reused across all files for consistency.

1. High background apoptosis in vehicle (>10%): cells over-confluent or aged — use log-phase cultures at 0.2-1.0 x 10^6/mL and gentle handling. 2. Weak Annexin V staining: ensure Ca2+ is present in binding buffer and do not wash cells in EDTA/PBS before staining. 3. Loss of the dying fraction: do not discard the floating cells in the supernatant during washes. 4. Spectral overlap/spillover into PI: run single-color controls and apply compensation; consider Annexin V-FITC with 7-AAD if PI spillover is severe. 5. PI signal drifting over time: add PI immediately before acquisition and read all tubes within 1 h on ice.

Percent apoptosis (AnnV+) per condition (mean of technical duplicates, n = 3 biological replicates) is analyzed by one-way ANOVA across doses with Dunnett's post-hoc test versus vehicle, alpha = 0.05. The time course is analyzed by two-way ANOVA (time x treatment) with Sidak correction. Z-VAD-FMK effect is tested by paired t-test versus matched staurosporine-only. EC50 is estimated by fitting a four-parameter logistic curve to the dose-response. With n = 3 and expected effect sizes >2 SD, power exceeds 0.9.